Real-world frequency and outcomes of intraocular inflammation-related adverse events in eyes with neovascular age-related macular degeneration treated with brolucizumab

被引：0
|
作者：
Mccoy, Jasmyne E. [1 ]
Zubricky, Ryan [2 ]
Donkor, Richard [1 ]
Miller, David G. [1 ]
Sonbolian, Nina [3 ]
Heaney, Andrew [3 ]
Bilano, Ver [3 ]
Karcher, Helene [3 ]
Coney, Joseph M. [1 ]
机构：
[1] Retina Associates Cleveland Inc, Beachwood, OH USA
[2] Geisinger Med Ctr, Danville, PA USA
[3] Novartis AG, Basel, Basel Stadt, Switzerland
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2023年 / 64卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
2216
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
    Yi-Sheng Chang
    Wan-Ju Lee
    Chen-Chee Lim
    Shih-Hao Wang
    Sheng-Min Hsu
    Yi-Chian Chen
    Chia-Yi Cheng
    Yu-Ti Teng
    Yi-Hsun Huang
    Chun-Chieh Lai
    Sung-Huei Tseng
    Scientific Reports, 8
  • [32] Real-world evidence for neovascular age-related macular degeneration: a practical approach
    Teo, Kelvin Yi Chong
    EYE, 2023, 37 (01) : 1 - 3
  • [33] Real-world evidence for neovascular age-related macular degeneration: a practical approach
    Kelvin Yi Chong Teo
    Eye, 2023, 37 : 1 - 3
  • [34] Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
    Chang, Yi-Sheng
    Lee, Wan-Ju
    Lim, Chen-Chee
    Wang, Shih-Hao
    Hsu, Sheng-Min
    Chen, Yi-Chian
    Cheng, Chia-Yi
    Teng, Yu-Ti
    Huang, Yi-Hsun
    Lai, Chun-Chieh
    Tseng, Sung-Huei
    SCIENTIFIC REPORTS, 2018, 8
  • [35] Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2 years: the REBA extension study
    Bilgic, Alper
    Kodjikian, Laurent
    de Ribot, Francesc March
    Spitzer, Martin S.
    Vasavada, Vaishali
    Gonzalez-Cortes, Jesus Hernan
    Sudhalkar, Aditya
    Chakraborty, Somnath
    Mathis, Thibaud
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2024, 262 (04) : 1161 - 1167
  • [36] Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
    Mehta, Neesurg
    Fong, Rodney
    Wilson, Machelle
    Moussa, Kareem
    Emami-Naeini, Parisa
    Moshiri, Ala
    Yiu, Glenn
    Park, Susanna S.
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 657 - 665
  • [37] Adverse Events Following Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration
    Pakravan, Parastou
    Shaheen, Abdulla
    Chau, Viet
    Lai, James
    Patel, Veshesh
    Yannuzzi, Nicolas
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [38] Brolucizumab in recalcitrant neovascular age-related macular degeneration-real-world data in Chinese population
    Weng, Chang-Chi
    Chi, Sheng-Chu
    Lin, Tai-Chi
    Huang, Yi-Ming
    Chou, Yu-Bai
    Hwang, De-Kuang
    Chen, Shih-Jen
    PLOS ONE, 2024, 19 (04):
  • [39] Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration
    Fauser, Sascha
    Viebahn, Ulrike
    Muether, Philipp S.
    ACTA OPHTHALMOLOGICA, 2015, 93 (08) : 734 - 738
  • [40] One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
    Cancian, Giuseppe
    Paris, Arianna
    Agliati, Lia
    Rizzato, Angelica
    Clerici, Michele
    Volpe, Giulio
    Menghini, Moreno
    Grimaldi, Gabriela
    OPHTHALMOLOGY AND THERAPY, 2024, 13 (11) : 2985 - 2997
12345